Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

benign prostatic hyperplasia

Astellas adds to US comms team

Marty Golden appointed VP, government affairs

- PMLiVE

Astellas picks PhRMA’s Uhlendorf for US public affairs lead

He will leave his role as VP, communications and public affairs at US trade body

- PMLiVE

AbbVie, Astellas and Roche teams among Communiqué finalists

2014 shortlist also includes MHP, Pegasus, Red Door, Ruder Finn and Virgo

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

- PMLiVE

Astellas backs fistula campaign

Supports efforts in Kenya to give women access to surgical treatment

National Institute for Health and Care Excellence NICE logo

NICE backtracks on prostate cancer drug enzalutamide

Says Astellas and Medivation's Xtandi can be used within the NHS in England and Wales

- PMLiVE

Xtandi on course for pre-chemo use in prostate cancer

US FDA grants priority review to Medivation and Astellas drug

- PMLiVE

Astellas uses animated bladder in campaign

Character in US advertisement for Myrbetriq constantly interrupts a woman with overactive bladder

- PMLiVE

Astellas sets up regenerative medicine unit

Will spearhead company's efforts in cell-based therapies

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

- PMLiVE

Xtandi filed as pre-chemo prostate cancer therapy

Astellas and Medivation look to extend uses of their prostate cancer drug

- PMLiVE

NICE backs Astellas’ Xtandi in prostate cancer

But company criticises restrictions imposed by HTA body for England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links